Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
